## REMARKS

In response to the restriction requirement set forth in the Office Action dated December 6, 2005, Applicants hereby provisionally elect Group IV (claims 27, 30, 33, 38, and 39) and the "TRANCE" cytokine species, for examination.

Purely for the sake of expediting examination, Applicants cancel the non-elected claims without prejudice or disclaimer. Applicants preserve the right to file one or more continuing applications to the canceled subject matter.

Claims 27, 30, 33, 38, 39, and 42-47 are pending. None of the original pending claims have been amended. Claims 42-47 are added and are commensurate with the elected group. Claims 42-47 do not introduce new matter, but are drawn to other embodiments, which Applicants consider to be their invention. In this respect, claim 42 qualifies the antigen of claim 27 to be encoded by a polynucleotide. Similarly, claims 43-47 are equivalent to the elected claim set, save that the recited antigen is encoded by a polynucleotide present in an expression cassette. Hence, the core carrier of claim 44 is coated with expression vectors that encode a desired peptide antigen, as well as the TRANCE cytokine. These claims are fully supported by the original specification and claims. See, for instance, page 23, lines 8-10, and page 25, first full paragraph.

Since none of the new claims introduce new matter, Applicants respectfully request their entry and examination alongside those of the elected group. The Examiner is invited to contact the undersigned if it is felt that a telephone discussion would expedite examination.

Respectfully submitted,

Date March 3, 2006

FOLEY & LARDNER LLP Customer Number: 22428

Telephone:

(202) 672-5483

Facsimile:

(202) 672-5399

By Vid Mohan-Ram

Registration No. 55,459

Richard C. Peet

Registration No. 35,792 Attorney(s) for Applicant